pre-IPO PHARMA

COMPANY OVERVIEW

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.


LOCATION


THERAPEUTIC AREAS


WEBSITE

None


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS

5am-ventures

PRESS RELEASES


Jun 22, 2021

Pear Therapeutics to Become a Public Company and Expand its Leadership Position in Prescription Digital Therapeutics


Jun 10, 2021

Pear Therapeutics to Participate in Cowen 6th Annual FutureHealth Conference


May 19, 2021

Pear Therapeutics Presents Results of Two Analyses Showing Decreases in Healthcare Resource Utilization and Associated Costs in Patients Using reSET-O in Treating Opioid Use Disorder


May 13, 2021

Pear Therapeutics to Participate in Citi Private Company Digital Health Conference


Apr 12, 2021

New Study, with Pear Therapeutics, to Identify Best Practices for Implementation in Primary Care of Digital Treatment for Substance Use Disorders


For More Press Releases


Google Analytics Alternative